Avalyn Pharma FY26 Q1 net loss widens to $26.87 million

• Avalyn Pharma posted a net loss of $26.87 million, widening from $17.5 million a year earlier.
• R&D expenses climbed to $22.89 million from $15.32 million, while G&A costs rose to $5.02 million from $3.4 million.
• Cash, cash equivalents, and marketable securities fell to $123.13 million as of March 31, excluding $316.1 million in IPO net proceeds.
• The upsized IPO raised $345 million in gross proceeds; cash including IPO proceeds is expected to fund operations into 2029.
• AP01 MIST Phase 2b enrollment is targeted to finish mid-2026 with topline data in 2H 2027; AP02 AURA Phase 2 topline data are expected in late 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalyn Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606030700PRIMZONEFULLFEED9731066) on June 03, 2026, and is solely responsible for the information contained therein.